Cydan

@Cydanco

Cydan, an orphan drug accelerator dedicated to creating therapies that improve the lives of patients living with rare genetic diseases.

Cambridge, MA
Vrijeme pridruživanja: veljača 2015.

Tweetovi

Blokirali ste korisnika/cu @Cydanco

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Cydanco

  1. 14. sij

    Proud to participate and sponsor Rare In the Square. Thanks to Global Genes and the other sponsors for bringing this important event to

    Poništi
  2. proslijedio/la je Tweet
    14. sij

    What a beautiful evening with my huge hearted friends from the industry. Patient oriented pharma going global

    Poništi
  3. 13. sij

    Cydan is excited to support Global Genes at the Rare in the Square event at

    Poništi
  4. proslijedio/la je Tweet
    14. stu 2019.

    Finally, ind. BOD members w/ the most orthogonal insights are also often least in-the-know on key operational aspects of the business. This can result in them disengaging, not speaking up much, etc. One way to address this to ask outside of mtgs what THEY see as risks/opp's. 5/5

    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet
    13. stu 2019.

    Cydan is pleased to support the 2019 IARC meeting in DC & collaborating to create new Rx for ataxias. This IARC is the largest ever with more companies, investigators and advocacy groups than any previous IARC. Congratulations

    Poništi
  6. 24. lis 2019.

    Cydan congratulates all the participants at MassChallenge 2019 to and is excited to support entrepreneurship

    Poništi
  7. 1. lis 2019.

    We're proud to have attended the Energy Ball! Pictured here is Ronald J. Bartek, President/Director/Co-Founder of FARA, and James McArthur, Founder and President of Cydan.

    Poništi
  8. 19. ruj 2019.

    We're excited to be participating in the Global Genes Rare Patient Advocacy Summit. If you're attending, swing by Imran's panel - Friday September 20 at 1:00

    Poništi
  9. 26. kol 2019.

    James and Ryan had a great time this weekend at Cycle 4 CMT, a fundraising ride for Charcot-Marie-Tooth, or CMT. If you’re interested in helping, consider donating at

    Poništi
  10. 23. kol 2019.

    This Saturday we’ll be riding for a good cause and fundraising to find a cure for people with Charcot-Marie-Tooth, or CMT, a progressive neurological disease. If you’re interested in helping, consider donating at

    Poništi
  11. 14. kol 2019.

    Please support the Cydan Cycling Team to support the CMT Association!

    Poništi
  12. 26. srp 2019.

    Cydan is excited to participate at the annual HNRNPH2 family meeting. Great scientific progress and increase in rate of patient identification => 100 patients soon!

    Poništi
  13. 25. srp 2019.

    Inspiring progress congrats Rohan - the Lydian Accelerator is moving at warp speed!

    Poništi
  14. 11. srp 2019.

    Our Co-Founder and President R&D, James McArthur, has been a part of the FARA board of directors and scientific advisory board for the last several years as part of our commitment to help advance meaningful treatments for patients with rare genetic diseases.

    Poništi
  15. 4. srp 2019.

    Happy Independence Day! Watch this inspiring story of the Seth family’s quest to accelerate a therapy to save their daughter Lydia

    Poništi
  16. proslijedio/la je Tweet
    3. srp 2019.
    Poništi
  17. 13. lip 2019.

    If you're attending the today, 's Imran Babar, PhD, will be part of a panel discussion during the Partnering & Investment track at 1:45 p.m. Under its collaborative model, Cydan has launched three new companies focused on rare disease.

    Poništi
  18. 11. lip 2019.

    's Imran Babar, PhD will be in Boston at the tomorrow to participate in a panel discussion on funding rare disease therapies. Cydan works with leading investors in to accelerate science to medicine.

    Poništi
  19. 7. lip 2019.
    Poništi
  20. 6. lip 2019.

    Our team is wrapping up a great week at . Thank you to for connecting the best in the industry and helping 's efforts to uncover compelling new science and promising drug candidates in .

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·